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RESUME 
Le rétinoblastome (Rb) est une tumeur provenant des cellules rétiniennes pro génitrices 
des photorécepteurs. C'est la tumeur pédiatrique maligne la plus fréquente avec une 
incidence par naissance évaluée entre 1115'000 et 1/20'000. Les enfants atteints de Rb 
sont diagnostiqué dans leur grande majorité avant l'âge de 4 ans, soit le temps nécessaire 
à la différentiation et à la maturation des photorécepteurs et donc à la disparition de la 
cellule d'origine du Rb. La survie du patient, la sauvegarde oculaire et le pronostic visuel 
restent excellents pour autant que le traitement ne soit pas différé. Dans sa variante non 
héréditaire (60%) le Rb est toujours unilatéral et sporadique. Le Rb héréditaire de 
transmission dominante autosomique ( 40% ), se décline sous toutes les formes, familiale 
(10%) ou sporadique (30%), que l'atteinte soit unilatérale ou bilatérale. 
La majorité des mutations causales sont uniques et distribuées de façon aléatoire sur la 
totalité du gène RB 1 sans région prédisposante. La détection de ces mutations est 
couteuse et chronophage, tout en présentant un taux de détection relativement bas; surtout 
dans les cas de Rb sporadiques unilatéraux. Dans le but d'identifier les patients 
présentant un risque réel de développer un Rb, et de réduire le nombre d'examens sous 
narcose requis pour le dépistage de la maladie chez les sujets à risque, nous avons 
développé une stratégie sensible, rapide, efficace et peu couteuse basée sur une analyse 
de l'haplotype intragénique. Cet algorithme prend en compte a) la perte d'hétérozygotie 
intratumorale du gène RBl, b) l'origine paternelle préférentielle des nouvelles mutations 
germinales et c) un risque a priori dérivé des données empiriques de Vogel. Pendant la 
période allant de janvier 1994 à décembre 2006, nous avons comparé l'apparition de 
nouveau Rb parmi la fratrie et la descendance de patient atteints au nombre de nouveaux 
cas attendus calculé par notre algorithme. 134 familles ont été étudiées. L'analyse 
moléculaire a été effectuée chez 570 personnes dont 99 patients âgés de moins de 4 ans et 
donc à risque de développer un Rb. Parmi cette cohorte, nous avons observé l'apparition 
d'un cas de Rb, alors que les risques cumulés a posteriori calculé par notre algorithme 
prédisait l'apparition de 1.77 nouveau cas. Dans cette étude, nous avons pu valider notre 
algorithme prédisant la récurrence de Rb chez les parents de 1er degré de patients 
atteints. Cet outil devrait grandement faciliter le conseil génétique ainsi que le suivi des 
patients à risque de développer un Rb, surtout dans les cas ou le séquençage direct du 
gène RBl n'est pas disponible ou est resté non informatif. 
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ABSTRACT 
Purpose: Most RBl mutations are unique and distributed throughout the RBl gene. Their detection can be 
time-consuming and the yield especially low in cases of conservatively-treated sporadic unilateral retinoblas-
toma (Rb) patients. In order to identify patients with true risk of developing Rb, and to reduce the number of 
unnecessary examinations under anesthesia in all other cases, we developed a universal sensitive, efficient 
and cost-effective strategy based on intragenic haplotype analysis. 
Methods: This algorithm allows the calculation of the a posteriori risk of developing Rb and takes into account (a) 
RBl loss of heterozygosity in tumors, (b) preferential pateri:ial origin of new germline mutations, (c) a priori risk 
derived from empirical data by Vogel, and ( d) disease penetrance of 90% in most cases. We report the occurrence 
of Rb in first degree relatives of patients with sporadic Rb who visited the Jules Gonin Eye Hospital, Lausanne, 
Switzerland, from January 1994 to December 2006 compared to expected new cases of Rb using our algorithm. 
Results: A total of 134 families with sporadic Rb were enrolled; testing was performed in 570 individuals and 
99 patients younger than 4 years old were identified, We observed one new case of Rb, Using our algorithm, 
the cumulated total a posteriori risk of recurrence was 1.77. 
Conclusions: This is the first time that linkage analysis has been validated to monitor the risk of recurrence 
in sporadic Rb. This should be a useful tool in genetic counseling, especially when direct RBl screening for 
mutations leaves a negative result or is unavailable. 
Keywords: Sporadic, retinoblastoma, recurrence, linkage analysis, genetic counseling 
INTRODUCTION 
Retinoblastoma (Rb) is the most common pediatric 
ocular malignancy and the most prevalent eye can-
cer around the world.1 Rb originates from progeni-
tors of retinal sensory cells, most probably along a 
cone lineage,2' 3 with an estimated incidence between 
1/18,000 and 1/20,000 live births.4,5 Affected children 
will develop Rb very early in life, during the period of 
cellular differentiation until the age of 4 years. Rb is 
still a mutilating, blinding and sometimes lethal disor-
der. There are two forms of Rb; familial and sporadic, 
the latter being the most widespread and accounting 
for more than 85% of the cases. 
Rb was a model for Knudson' s two hit hypothesis. 6 
In his initial hypothesis, he stated that two mutational 
Received 02 November 2010; revised 08 July 2011; accepted 17 July 2011 
events were required for the initiation of Rb. Later, it 
was shown that these two mutational events inacti-
vate both alleles of a single gene. Current knowledge 
indicates that mutations affecting both alleles of the 
Rb susceptibility gene (RBl) are a prerequisite for the 
development of this tumor.6--8 In .most patients with 
sporadic unilateral Rb, the two RBl gene mutations 
that initiate tumor development are somatic events, 
and none are present in DNA from constitutional 
cells.9- 11 In fact 10-15% of them carry either homo-
geneous or mosaic mutations (see the description of 
the algorithm below). Patients with sporadic bilateral 
or familial retinoblastoma are heterozygous for an 
RBl gene mutation that was either inherited from an 
affected parent or that occurred de novo in parental 
germline cells. 
Correspondence: Francis Munier, MD, Jules Gonin Eye Hospital, 15, Avenue de France, 1004 Lausanne VD, Switzerland. Tel: +4121626 85 82. 
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Management of affected individuals also takes into 
account genetic counseling to relatives at risk. Genetie 
counseling of sporadic Rb can either be based on 
empirical risk calculations12 or on the segregation of 
RBl mutant alleles. In the former case, identification 
of disease recurrence relies on systematic examination 
under anesthesia (EUA) of all first degree relatives irre-
spective of their genetic predisposition from birth until 
4 years of age; while in the latter, only the RBl mutant 
carriers are investigated. Unfortunately, the underly-
ing technology that leads to the oncogenic mutation 
is only available to limited number of patients around 
the world and is still expensive and time-consuming. 
Additionally, because the inactivating mutations are 
highly heterogeneous and distributed along the entire 
coding sequence of the gene, some 90% of sporadic 
unilateral Rb and 12-25% of sporadic bilateral Rb have 
undetected mutation despite all mutational screening 
efforts,13-16 leaving more than 50% of families without 
molecular diagnosis and accurate genetic counseling of 
the disease. This prompted us to develop and validate 
an algorithm based on linkage analysis in a large popu-
lation at risk to improve genetic counseling and disease 
follow-up in comparison to classical systematic EAU 
in patients at risk with sporadic Rb. Thus, the primary 
goal of molecular testing is to identify individuals with 
significant risk while avoiding repeated examinations 
in those with minimal risk. 
MATERIAlS AND METHODS 
Patients 
All consecutive patients with uni- or bilateral sporadic 
Rb including their first degree relatives seen between 
January 1994 and December 2006 at the Jules Gonin 
Eye Hospital were enrolled. Patients were referred 
from several countries, mostly Switzerland, Italy, 
Portugal and Greece. Written informed consent was 
obtained from all patients and members of the family 
using a consent form approved by the Swiss Federal 
Office of Public Health (035.0003-48) for Clinical 
Research and following the tenets of the Declaration 
of Helsinki. 
All patients at risk were defined as siblings or chil-
dren of affected Rb patients younger than 4 years of 
age. They were followed until the age of 48 months and 
automatically assigned a follow-up under narcosis at 
1, 3, 6, 10, 15, 21, 28, 36 and 42 months as customary. 
Occurrence of new patients with Rb among this popula-
tion was noted and compared to the predicted number 
of expected cases using our algorithm. 
From January 1994 to July 2003, molecular char-
acterization of RBl alleles was performed using 
intra/ extragenic sequence polymorphisms such as 
restriction fragment length polymorphisms (RFLP), 
variable number of tandem repeats (VNTR) sequences, 
© 2012 Informa Healthcare USA. lnc. 
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and microsatellites, as listed in Table 1. From August 
2003 to December 2006, polymorphie short tandems 
(STR) were used as recommended by the Best Practice 
Guidelines of the European Molecular Genetics 
Quality Network (EMQN) for linkage analysis of 
RBl (Table 2).17 The calculated risks obtained with 
our algorithm were then cumulated to allow compari-
son with the observed occurrence of retinoblastoma 
in this cohort. 
MolecularTesting 
Hybridization to cDNA Probe 
Genomic DNA from peripheral blood leukocytes and 
tumoral tissue (from fresh tumors) was digested with 
SOU of HindIII. The resulting fragments were sepa-
rated onto 0.8% agarose-gel, and blotted onto nylon 
membrane.18 The filters were hybridized overnight at 
42°C with the p4.95BT probe labeled with digoxigenin. 
After removal of the unbound probe, the bands were 
detected using a chemiluminescent substrate for alka-
line phosphatase.19 
Analysis with Polymorphie Markers 
The polymorphie markers used in this study are shown 
in Tables 1 and 2. Three of the RFLPs were studied by 
PCR-amplification of the fragments, and the digestion 
of the product was electrophoresed in polyacrylamide 
or agarose gel and detected by silver-staining with slight 
modifications, or ethidium bromide. The VNTR marker 
is detected by Southern blotting. 
The analysis of microsatellite markers is carried out 
by PCR amplification and electrophoresis in an auto-
mated sequencing machine.20 
TABLE 1 Location of the different polymorphie markers. 
Polymorphie marker Probes Location 
Apa 1 E5D 14.1.1 E5D 
BamHI 123M 1.8 Intron 1 
Kpnl 95H5 0.5 Intron4 
Hind III H3-8 Exon4 
Xbal 88R2.5 Intron 17 
Xba 1 (1-20 mierosatellites) 88R2.5 Intron 20 
Rsal (VNTR) 68R52.0 Intron 17 
Tth III 1 (Aspl) 35R0.6 Intron 24 
TABLE 2 Polymorphie short tandems (5TRs) within and linked 
to the retinoblastoma (RBl) gene. 
Markername Location Accession 
0135161 Centromerie to RBl (l.lMb) Zl6802 
0135287 Centromerie to RBl (l.OMb) Z24331 
0135164 Centromerie to RBl (0.05Mb) Z16858 
0135153 RBl: intron 2 Z16494 
Rbl.20 RBl: intron 20 
01351307 Telomerie to RBl (0.25Mb) Z51671 
0135165 Telomerie to RBl (0.9Mb) Zl6900 
0135273 Telomeric to RBl (1.25Mb) Z23383 
RIGMTS 
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Description of the Algorithm 
We designed an algorithm based on haplotype character-
ization of both RBl alleles applicable to all familles. This 
algorithm combines segregation analysis using RBl poly-
morphie markers21 and is based on: (a) a priori risk derived 
from empirical data by Vogel,22 (b) preferential patemal 
origin of new germline mutations,23•24 (c) analysis of loss 
of heterozygosity (LOH) in the tumor,25 (d) and disease's 
penetrance of 90% in most cases,15 although it can vary 
significantly according to the mutation's type.14 
In bilateral sporadic cases of Rb, risks have been 
empirically calculated by Vogel as follows: the a priori 
recurrence risk is 6% for siblings, whereas the a priori 
transmission risk is 50% for the offspring. 22 If LOH is 
present in the tumor, the haplotype linked to the predis-
posing germline mutation can be identified. This in tum 
allows us to accurately predict the risk (Fig. lA): 
• 2x6%=12% risk if the retained haplotype is passed 
to the sibling, versus 1/20,000 (exclusion) if not. 
• 2x50%=100% risk if the retained haplotype is 
transmitted to offspring, versus 1/20,000 (exclu-
sion) if not. 
If LOH is not detected or if no tumoral material is 
available for analysis, the risk will be modified accord-
ing to inheritance of grandparental alleles (Fig. lB): 
A 
Retained allele 
trnnsmittcd 
R=l2% 
Retained allele 
not trnnsmittcd 
R=l/20'000 
B 
• 2 x 6% = 12% risk for the sibling if the same paren-
tal alleles are transmitted; 2 x 6 x 90% = 10.8% if 
the paternal allele is transmitted (preferential 
paternal origin of new germline mutations in 
90% of cases;23 2x6x10%=1.2% if the materna! 
allele is transmitted and 1/20 ,000 if both alleles 
are distinct. 
In unilateral sporadic Rb, the a priori recurrence risk is 
1 % for siblings, whereas the a priori transmission risk is 
6% for the offspring. If LOH is present in the tumor, the 
haplotype linked to the predisposing germline muta-
tion can be identified. This in turn allows the accurate 
prediction of the risk (Fig. lC): 
• 2 x 1%=2% risk if the retained haplotype is passed 
to the sibling, versus 1/20,000 (exclusion) if not. 
• 2x6%=12% risk if the retained haplotype is trans-
mitted to offspring, versus 1/20,000 (exclusion) 
if not. 
If LOH is not detected or if no tumoral material is 
available for analysis, the risk will be modified accord-
ing to inheritance of grandparental alleles (Fig. 10). In 
unilateral Rb, the probability of a de-novo event occur-
ring preferentially in the paternal germline is lower 
than the 90% reported in bilateral cases. An estimate 
of this probability can be derived from the study of 
Schüler.24 This study found that 54% of constitutional 
Same patemal Same maternai 
allclc R=I0.8 % allclc R=l.2 % 
Same parental Distinct parental 
allclcs R=l2 % allelcs R=l/20000 
Retained allele 
trnnsmilted 
R=IOO% 
Retained allele 
no11rnnsmittcd 
R=d/20'000 
Grand patcmal Grand patcmal allele 
c 
Retained allele 
trunsmitted 
R=2% 
Retaincd allelc Retained allele 
transmitted 
R=l2% 
not transmittcd 
R=l/20'000 
Retained allelc 
not transmitted 
R=l/20'000 
allele trnnsmittcd not tnmsmitted 
Ro=90% R=IO% 
D 
Same paternal Same maternai Sume parental Distinct parental 
allé!~ R=IA <;,, allde R=O.C1 q. alleles R=2 % alleles R=l/20000 
Grand paternal Retained allele 
allele transmitted not trarnmittcd 
R=~Ui •;; R=JA 'i<· 
FIGURE 1 (A) Presence of loss of heterozygosity (LOH). Modification of risk in offspring (a priori risk=50%) and in siblings (a priori 
risk=6%) of bilaterally affected proband. (B) Absence of LOH. Modification of risk in offspring (a priori risk=50%) and in siblings 
(a priori risk=6%) of bilaterally affected proband. (C) Presence of LOH. Modification of risk in offspring (a priori risk=6%) and in 
siblings (a priori risk = 1 %) of unilaterally affected proband. (D) Absence of LOH. Modification of risk in offspring (a priori risk = 6%) and 
in siblings (a priori risk= 1 %) of unilaterally affected proband. 
RBl mutations in sporadic unilateral Rb were de nova, 
29% mosaics in nature, and 17% transmitted from 
an unaffected parent (incomplete penetrance, two 
from the father and two from the mother). Therefore, 
the preferential paternal origin in cases of sporadic 
unilaterally affected patients can be estimated at 
90% x 54 + 50% x 46 == 72% [90% (preferential paternal 
origin) of 54% (de nova mutants) + half (absence of 
preferential paternal origin) of 46% (mosaic and trans-
mitted mutants)]: 
• 2 x 1%==2% risk if the same parental alleles are 
transmitted to the sibling, 2x1x72%==1.4% if the 
paternal allele is transmitted, 2 x 1 x 28% == 0.6% if the 
maternal allele is transmitted and 1/20,000 if bath 
alleles are distinct. 
• 2 x 6 x 72% == 8.6% risk in case of inheritance of 
the grandpaternal haplotype in offspring, versus 
2 x 6 x28%==3.4% for the grandmaternal. 
Finally the new modified calculated risk of Rb's 
recurrence was adjusted to a penetrance of 90%.15 
The siblings and offspring of affected patients were 
then classified into two categories: (a) low-risk ('.>l.08 
%), and (b) significant-risk (>1.08%). 
RESULTS 
A total of 304 kindreds with sporadic Rb were enrolled 
and analyzed. Out of these 304 index patients, 134 had 
first degree relatives and were included. Seventy-nine 
(59%) Rb patients were unilateral and 55 (41 %) bilateral. 
Linkage analysis was based on the segregation of the 
RBl allele in a total of 570 individuals. There were 168 
first degree relatives of the index patient. Eighty-four 
out of 146 siblings, 15 out of 22 offspring who were 
younger than 48 months of age at the time of the linkage 
analysis and older than 48 months of age by December 
2006, were enrolled. Mean age was 26.9±17.2 months 
(range from birth to 47 months of age). Mean follow up 
time was of 60.8±15.7 months. 
Classical Clinical Follow-up 
During this time, one new case of Rb was diagnosed 
from among the sibling's group at 8 months of age; 
from a significant-risk relative Rb's recurrence of 
1.4x90%==1.26% upon our algorithm, 6 months after 
the first examination and linkage analysis. It was a 
unilateral Rb due to a R255X mutation, stage C (ABC 
classification) that was successfully cured by conser-
vative therapy consisting of chemo-, thermo-, and 
cryo-therapy without radiotherapy. The remaining 
patients were followed until the age of 4 years and 
did not develop Rb. All the patients (n == 69) older than 
4 years were also examined clinically and none of them 
hadRb. 
© 2012 Informa Healthcare USA. lnc. 
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TABLE 3 New cumulated calculated recurrence risk of 
retinoblastoma. 
Number of Significant 
patients Low risk risk 
Siblings 61 23 
Offspring 8 7 
Cumulated 
calculated risk (%) 
116.2 
61.3 
Expected Occurrence of New Patients with Rb 
using our Algorithm 
Linkage analysis was informative in 129 (96%) families. 
Molecular analysis of tumor tissue identified 23 LOH 
out of 38 (61 %). Sixty-one of these siblings were classi-
fied as low-risk of which 21 were at no risk given the 
inheritance of an entirely different haplotype than the 
proband and 23 patients were considered at significant 
risk. 
Eight of 15 offspring were at minimal risk of which 
one was at no risk. Seven patients were of significant 
risk. The data are summarized in Table 3. 
Applying our algorithm to this cohort of patients, we 
expected 1.77 new declared cases of Rb (cumulated risk 
of recurrence: 1.162 for the siblings group and 0.613 for 
the offspring) during the pre-defined follow-up period. It 
should be noted that none of the patients with a different 
haplotype to the index patient developed Rb and that the 
new Rb patient occurred in the group at significant risk. 
DISCUSSION 
Retinoblastoma is a malignant tumor that originates 
from progenitors of retinal sensory cells. Affected chil-
dren will therefore develop Rb very early in life, dur-
ing the period of cellular maturation. In contrast, Rb is 
extremely rare in adults, where it sometimes arises from 
retinoma, a related benign lesion. 
Survival rate and prevention of blindness in Rb 
patients depend on accurate and early diagnosis. If 
Rb is newly diagnosed in a family, examination of the 
retina is mandatory in all relatives at risk to exclude 
the presence of retinal tumor. Genetie counseling is 
required to identify relatives with an increased risk. If 
relatives at risk are still in early childhood, repeated 
EUAs are mandatory. Therefore, the primary goal of 
molecular testing is to identify high-risk individuals 
while avoiding repeated examinations (a total of nine 
EUAs is necessary to caver the period of potential 
retinal oncogenesis). Classically, genetic counseling of 
families with sporadic Rb has been based on a priori 
risk derived from the compilation of empiric data.22 
The a priori risk of recurrence for siblings of sporadic 
bilateral Rb patients is 6% and 50% for offspring. In 
sporadic unilateral Rb, these risks are 1 % and 6% 
respectively. All patients at risk are then placed under 
a rigorous program of ophthalmoscopic EUA, despite 
the fact that only a fraction of them has inherited the Rb 
RtOHTS 
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predisposition. To overcome the genetic burden in rela-
tives of index Rb patients, it has been proposed more 
recently to screen directly for the presence of the dis-
ease-causing RBl mutation. Noorani demonstrated that 
identification of the oncogenic mutation is cost-effective 
when compared to conventional screening consisting 
of repeated EUAs.13 However, their study was based 
on molecular scanning of the 180-Kb RBl gene, which 
is hampered by a low yield of only 40-45% (80-90% in 
bilateral cases and 10-15% in unilateral cases). In other 
words, a significant proportion of families are left with-
out molecular diagnosis. This suggests that, nowadays, 
no single methodology will be fully sensitive, accurate 
and economic. 
In the current study, an algorithm based on linkage 
analysis identified patients with true risk, except in situ-
ations where a sporadic unilateral Rb patient is a low 
proportion mosaic for a large RBl gene deletion. In such 
a case the risk would be overestimated in the sibling, 
whereas the risk prediction in the offspring would tend 
towards either overestimation or loss of informativity. 
This strategy is efficient (informative in 96% of the fami-
lies) and can be universally applied. More importantly, 
the expected recurrence risk of Rb in relatives was in 
accordance with the natural observed recurrence rate in 
our cohort without false negative cases. Applying our 
algorithm, we would have been able to avoid unneces-
sary EUA surveillance in 69 of 99 (69.7%) patients, with 
a total of 362 EUAs circumvented. Therefore patients at 
significant risk should be automatically assigned to a 
follow-up under narcosis until 4 years of age, although, 
Abramson reported that the majority of the Rb is diag-
nosed before the age of 28 months.26 While in minimal-
risk patients, this heavy surveillance can be replaced by 
a regular ophthalmoscopy without anaesthesia. 
RFLP and VNTR analysis are less used and our insti-
tution has been primarily proceeding with direct muta-
tion screening since 2006. However, when necessary, we 
are using polymorphie short tandems (STR) as recom-
mended by the Best Practice Guidelines of the European 
Molecular Genetics Quality Network (EMQN) for indi-
rect testing of RBl.17 This algorithm represents a good 
alternative when mutational screening failed to identify 
the disease-causing mutation. It is also a cost-effective 
approach in centers with limited financial resources. 
In addition, linkage analysis has never been validated 
for the detection of risk recurrence in sporadic cases of 
Rb and the present algorithm proved to be reliable in 
a long-term follow up to modify the a priori risk of Rb 
transmission. 
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